Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Gets Price Target Bump from JPMorgan Chase & Co.

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by JPMorgan Chase & Co. from $560.00 to $570.00 in a report released on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 5.94% from the stock’s previous close.

Several other equities research analysts have also issued reports on VRTX. The Goldman Sachs Group lifted their price target on Vertex Pharmaceuticals from $654.00 to $725.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 16th. Royal Bank Of Canada boosted their target price on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research report on Tuesday. Morgan Stanley decreased their target price on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Sanford C. Bernstein upgraded shares of Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $596.11.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded down $15.13 during midday trading on Tuesday, hitting $538.02. 1,291,470 shares of the stock were exchanged, compared to its average volume of 1,388,738. Vertex Pharmaceuticals has a 52-week low of $403.16 and a 52-week high of $568.67. The business’s fifty day simple moving average is $523.32 and its two-hundred day simple moving average is $479.96. The company has a market capitalization of $136.55 billion, a PE ratio of 31.28, a P/E/G ratio of 2.54 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the firm earned $4.80 EPS. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. As a group, equities analysts anticipate that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. MADDEN SECURITIES Corp bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $26,000. Meeder Asset Management Inc. bought a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $26,000. Community Financial Services Group LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $26,000. Elevation Wealth Partners LLC increased its stake in shares of Vertex Pharmaceuticals by 103.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 28 shares during the period. Finally, Pingora Partners LLC bought a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $32,000. Institutional investors own 90.96% of the company’s stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product growth exceeded expectations. Third-quarter revenue rose 11.8% year over year to $3.44 billion, topping the $3.42 billion consensus estimate. Cystic fibrosis sales remained strong as Alyftrek gains share from Trikafta, while newer products CASGEVY and JOURNAVX continued to ramp. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 sales outlook to $13.2 billion-$13.3 billion, reflecting continued commercial momentum and an increasingly diversified product portfolio. Vertex Raises 2026 Earnings Guidance
• Positive Sentiment: Analysts largely became more constructive. Goldman Sachs raised its target to $725 and kept a Buy rating; Scotiabank, UBS, Wells Fargo, RBC, Cantor Fitzgerald, TD Cowen and Stifel also increased targets, with ratings ranging from Hold to Buy. The revisions indicate Wall Street sees additional upside from new launches and pipeline expansion.
• Positive Sentiment: Longer-term growth opportunities are expanding. Management is building additional commercial pillars in nephrology and rare endocrinology, including assets gained through the Crinetics acquisition. Vertex: Three Key Takeaways for Long-Term Investors
• Neutral Sentiment: Morgan Stanley lowered its target modestly to $660 but maintained an Overweight rating, suggesting confidence remains intact despite more cautious assumptions.
• Negative Sentiment: Quarterly profitability missed expectations. Adjusted EPS was $4.76, below estimates of approximately $4.82-$4.92 and down from $4.80 a year earlier. Spending on new launches and the Crinetics transaction limited earnings growth despite higher sales. Vertex Misses Q3 Earnings Estimates
• Negative Sentiment: The new revenue range broadly aligns with consensus rather than materially exceeding it, leaving investors focused on whether pipeline investments can translate into stronger future earnings.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.